Generex Biotechnology Corp. (fka GNBTQ)

[WeeZuhl]

Impressive and Robust

Dr. Kirsner, one of the Principal Investigators for the pivotal trial of Excellagen, and a lead author of the publication, presented findings of the MATRIX Study, published in the peer-reviewed Journal of Wound Repair and Regeneration (Wound Rep Reg (2011)19 302-308). Dr. Kirsner emphasized the “impressive healing rates obtained in the study,” and commented on the “the robust quality of the data” obtained in the MATRIX Study, which is the only randomized clinical trial that has been conducted in both the collagen and flowable markets.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443373/pdf/wrr0019-0302.pdf

The numerically greater complete closure incidence over SOC observed in the GAM501 and FCG groups was not statistically significant; whether the lack of significance was due to small sample size could be determined by future studies.

The finding that 35 of 113 (31%) patients were excluded
when the primary data was photographs is noteworthy.

So this is what my wife means all these years when she tells me I am impressive and robust? Small sample size? Not statistically significant? Sounds like she will get an invite if I ever host an Advisory Board Meeting.